

Advanced Single-Molecule Detection to Accelerate Biomarker Research

Singulex[®]



Eric Cevoz-Goyat, DVM - MBA, GM EU Lifesciences Operations

- Founded in 2004, 80 employees, headquartered in Alameda, CA
- Pioneer in high-definition immunoassay systems
- Strong IP portfolio & patented technology
- Pharma product launch in 2007
- CLIA certified laboratory since 2008
- European HQ in Lyon (France) since 2010




**Full Commercial Launch in 2011 of
Erenna Immunoassay System and Assay Menu**

Proprietary Digital Immunoassay Technology


PLAY VIDEO

<http://www.singulex.com/technology.htm>




Sensitivity : 40 to 100X improvement vs currently available technologies

- Vs ELISA : 100x lower LLoQ
- Vs MSD/ECL
 - 40x improvement in LoD
 - 50x Improvement in LLoQ





Assess baseline levels in healthy subjects
Lower sample volumes needed
Highly sensitive monitoring




A leap forward in biomarkers identification,
validation and monitoring

A full offer for taylor made solutions

- Menu of immunoassays
- Assay development
- Sample testing (validation study, POC...)
- Erenna single molecule counting platform




Efficient technology transfer across multiple phases of development and partnerships



Lyon : a strategic location for Singulex

- Provide support to EU customers
- Drive R&D activities
- Secure strong partnership with Indicia



Looking forward to discussing new R&D / commercial opportunities with regional partners



Singulex®

Contact us !

Eric Cevoz-Goyat, DVM-MBA, GM EU Lifesciences Operations

e.cevoz-goyat@singulex.com

Nathalie Rousselot, PhD

Research Project Mgr; EU Application & Technical Services

n.rousselot@singulex.com

May 10, 2011